Investors

Press Release Details

Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

April 15, 2021 at 7:00 AM EDT
PDF Version

MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference.

Details of the event are as follows:
Panel: Gamma Delta CART-Cells, and “Squeezed” T-cells
Date: Thursday, April 15, 2021
Time: 1:00 – 1:55 PM ET
Format: Panel moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst

About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com


Primary Logo

Source: Adicet Bio